Advertisement for orthosearch.org.uk
Results 1 - 2 of 2
Results per page:
The Bone & Joint Journal
Vol. 98-B, Issue 3 | Pages 387 - 394
1 Mar 2016
Eguchi Y Oikawa Y Suzuki M Orita S Yamauchi K Suzuki M Aoki Y Watanabe A Takahashi K Ohtori S

Aims

The aim of this study was to evaluate the time course of changes in parameters of diffusion tensor imaging (DTI) such as fractional anisotropy (FA) and apparent diffusion coefficient (ADC) in patients with symptomatic lumbar disc herniation. We also investigated the correlation between the severity of neurological symptoms and these parameters.

Patients and Methods

A total of 13 patients with unilateral radiculopathy due to herniation of a lumbar disc were investigated with DTI on a 1.5T MR scanner and underwent micro discectomy. There were nine men and four women, with a median age of 55.5 years (19 to 79). The changes in the mean FA and ADC values and the correlation between these changes and the severity of the neurological symptoms were investigated before and at six months after surgery.


Orthopaedic Proceedings
Vol. 86-B, Issue SUPP_IV | Pages 431 - 431
1 Apr 2004
Iwata H Ito H Hasegawa Y Ishiguro N Matsuda T Kitamura S Iyoda K Yabe Y Yamauchi K Kaneko H Maruno S
Full Access

Hydroxyapatite (HA) is a bioactive material with a high affinity for bone. Ti-6Al-4V is lightweight and less biotoxic. Using these materials, a cementless hip prosthesis has been clinically used, consisting mainly of a Ti femoral stem coated with plasma-sprayed biocompatible HA. However, this type of stem entails several disadvantages: HA is likely to decompose at the coating; long term HA coating layer bonding to Ti is unstable and optimal HA thickness is unfeasible. In many actual cases, debonding of HA coating layer from the Ti surface was found upon removal of stems.

To resolve these concerns, we started developing a new hip prosthesis using composite materials comprised of Ti-6Al-4V and HA containing bioinactive and highly stable glass in 1985. The cementless hip prosthesis, named HAPG-Profile, unites the bioactive stem surface with the surrounding bone via adhesive glass. In basic experiments, the glass-coated HAPG-Profile has been demonstrated to possess much higher bonding stability than the plasma-sprayed HA, with bone affinity and safety not compromised. On the basis of these results, we manufactured the HAPG-Profile jointly with DePuy International, UK, and initiated a clinical trial in January 1997 in the teaching Hospital, Nagoya University School of Medicine, and Tokyo Kosei Nenkin Hospital. A total of 63 patients were followed up for more than two year and evaluated according to the Japanese Orthopedic Association Score and Harris Hip Score (HHS) clinically, functionally and radiographically. The results of the two-year follow-up study indicated success of early fixation associated with favorable outcomes.